Status:

COMPLETED

Bioavailability of Different n-3 Fatty Acid Formulations

Lead Sponsor:

Gottfried Wilhelm Leibniz Universität Hannover

Conditions:

Health

Eligibility:

MALE

20-50 years

Phase:

PHASE4

Brief Summary

The aim of this study is to examine differences in short term bioavailability between four n-3 FA formulations in healthy males.

Detailed Description

The long-chain n-3 fatty acids (n-3 FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are known to positively affect the lipid profile, vascular tone and blood coagulation. Moreover, EPA...

Eligibility Criteria

Inclusion

  • males,
  • 20-50 years,
  • Caucasian,
  • healthy,
  • body mass index (BMI) 20-28 kg/m²,
  • no medical treatment,
  • written confirmation of the subjects after detailed spoken and written explanation about the study contents,
  • ability and willingness of the participants to attend the investigator's orders (compliance of the study conditions, consumption of the study drugs according to the dosage commendation

Exclusion

  • medical treatment (especially corticosteroids, anti-inflammatory drugs, blood lipids lowering drugs (e.g. statines, fibrates, bile acid exchanger resin, phytosterols)
  • taking any supplements with n-3 FAs, phytosterols, polyglucosamines (Chitosan) or other lipid binding ingredients
  • daily consumption of n-3 FAs rich fish (salmon, mackerel, herring)
  • heavy chronic diseases (tumors, diabetes typ 1, etc.), documented heart disease, documented blood clotting disorders, renal failure, liver diseases
  • documented blood clotting disorders and consumption of coagulation-inhibiting drugs (for example Marcumar, ASS)
  • allergy or intolerance to fish/fish oil or any of the study ingredients of the test products
  • chronic gastro-intestinal diseases (Colitis ulcerosa, Morbus Crohn, pancreatic insufficiency)
  • donation of blood in the last 6 weeks
  • routine consumption of laxative
  • alcohol-, drug- and/or medicament dependence
  • subjects who are not in agreement with the study conditions
  • refusal or rather reset of the consent from the subject
  • active participation in other investigational drug or device trial within the last 30 days

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2011

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT01214278

Start Date

October 1 2010

End Date

July 1 2011

Last Update

December 7 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gottfried Wilhelm leibniz University of Hanover

Hanover, Lower Saxony, Germany, 30167